West Pharma (WST) Tops Q4 EPS by 13c, Offers Guidance

West Pharma (NYSE: WST) reported Q4 EPS of $2.04, $0.13 better than the analyst estimate of $1.91. Revenue for the quarter came in at $730.8 million versus the consensus estimate of $710.2 million.

GUIDANCE:

West Pharma sees FY2022 EPS of $9.20-$9.35, versus the consensus of $9.06. West Pharma sees FY2022 revenue of $3.05-3.075 billion, versus the consensus of $3.07 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Lucid reports Q2 output, names new CFO and five other leaders
• Moomoo launches paid trading toolkit called Moomoo Engine
• Aecon wins $1.7B share of Alberta power plant contract